Molbio Diagnostics Limited IPO Details

Incorporated in 2000, Molbio Diagnostics Limited is a point-of-care (“POC”) diagnostics company focused on delivering accurate, rapid, and cost-effective healthcare technologies for infectious and non-communicable diseases.

The company has developed the ‘Truenat’ platform, a portable polymerase chain reaction (“PCR”) system that provides decentralized diagnosis within an hour, even in resource-limited settings. As of March 31, 2025, the platform is patented in over 100 countries and offers molecular testing for 30 diseases, including tuberculosis (TB), COVID, Hepatitis B and C, HIV, and HPV through 42 assays. The ‘Truenat’ TB test is one of only two WHO-endorsed rapid molecular tests for initial TB diagnosis and rifampicin resistance detection.

The company also provides radiology, digital pathology, and breast health screening solutions through its subsidiary Prognosys, associate OptraScan, and collaboration partner UE Lifesciences.

The company operates five manufacturing facilities in India – two in Goa, one in Visakhapatnam (Andhra Pradesh), and two in Bengaluru (Karnataka). These units manufacture diagnostic devices, test kits, and radiology products such as ultraportable and mobile X-ray systems.

The company has a global presence in over 80 countries with 33 international distributors and has sold more than 10,000 devices as of March 31, 2025. Products are supplied directly and through distributors to public health programs, diagnostic laboratories, and hospitals.

The company generates revenues from device sales as well as recurring revenues from proprietary test kits.

As of March 31, 2025, the company employed 1,000 permanent employees and 1,511 contract labourers.